<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19099">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858258</url>
  </required_header>
  <id_info>
    <org_study_id>TRIANGLE</org_study_id>
    <nct_id>NCT02858258</nct_id>
  </id_info>
  <brief_title>ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma</brief_title>
  <official_title>Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. M. Dreyling (co-chairman)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Mantle Cell Lymphoma Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the the trial is to establish one of three study arms, as future
      standard based on the comparison of the investigator-assessed failure-free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives and Endpoints

      Primary Objective:

      To establish one of three study arms, R-CHOP/R-DHAP followed by ASCT (control arm A),
      R-CHOP+ibrutinib /R-DHAP followed by ASCT and ibrutinib maintenance experimental arm A+I),
      and R-CHOP+ibrutinib /R-DHAP followed by ibrutinib maintenance experimental arm I) as future
      standard based on the comparison of the investigator-assessed failure-free survival (FFS).

      Secondary Objectives:

        -  To compare the efficacy of the three treatment arms in terms of secondary efficacy
           endpoints

        -  To determine the safety and tolerability of ibrutinib during induction
           immuno-chemotherapy and during maintenance and to compare the safety profile of the
           three treatment arms in terms of secondary toxicity endpoints

      Primary Endpoint:

      FFS defined as time from start of treatment to stable disease at end of immuno-chemotherapy,
      progressive disease, or death from any cause.

      Secondary Efficacy Endpoints:

        -  Overall survival (OS)

        -  Progression-free survival (PFS) from randomization, from end of induction
           immuno-chemotherapy in patients with CR or PR at end of induction immuno-chemotherapy,
           and from the staging 6 weeks after end of induction assessment (at month 6)

        -  Overall response and complete remission rates at midterm, at end of induction, 3 months
           after end of induction immunochemotherapy (at month 6)

        -  PR to CR conversion rate during follow-up after end of induction immuno-chemotherapy

      Secondary Toxicity Endpoints:

        -  Rates of AEs, SAEs, and SUSARs by CTC grade (Version 4.03) during induction
           immuno-chemotherapy and during periods of follow-up after response to
           immune-chemotherapy

        -  Cumulative incidence rates of SPMs

      Exploratory Objectives:

        -  To compare feasibility of ASCT in arm A+I vs. arm A

        -  To compare minimal residual disease status between the three treatment groups

        -  To determine the impact of ibrutinib during induction immuno-chemotherapy and during
           maintenance therapy on the minimal residual disease status

        -  To determine the prognostic value of minimal residual disease status

        -  To determine the prognostic value of positron emission tomography with fluorine
           18-fluorodeoxyglucose

        -  To determine clinical and biological prognostic and predictive factors

        -  To determine the role of total body irradiation (TBI) in ASCT conditioning

      Exploratory Endpoints:

        -  Rate of successful stem cell mobilisations (success: separation of at least 2x2x10(6)
           CD34-positive cells, including a back-up)

        -  Rate of molecular remissions (MRD-negative patients) at midterm, at end of induction
           immuno-chemotherapy, and at staging time-points during follow-up in patients with
           remission after end of induction immuno-chemotherapy

        -  Time to molecular remission from start of therapy

        -  Time to molecular relapse for patients in clinical and molecular remission after end of
           induction immunochemotherapy

        -  RD in FDG-PET negative or positive patients after induction and ASCT

      Exploratory objectives may be evaluated only in a subset of patients according to local
      standards and resources.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure Free Survival</measure>
    <time_frame>From start of treatment until stable disease at end of immuno-chemotherapy, progressive disease, or death from any cause, whichever comes first, assessed up to 120 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From start of treatment until the date of first documented progression, assessed up to 120 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTC Version 4.03</measure>
    <time_frame>From start of Ibrutinib treatment during induction immuno-chemotherapy and during maintenance and to compare the safety profile of the three treatment arms in terms of secondary toxicity endpoints. Through study conduction, an average of up to 30 months.</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>PFS is the time to progression or death from any cause. Assed up to 120 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Secondary Primary Malignancies</measure>
    <time_frame>From start of treatment through the study conduction, up to 120 months.</time_frame>
    <description>Toxicity Endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events by CTC grade (Version 4.03)</measure>
    <time_frame>From start of treatment through the study conduction, up to 120 months.</time_frame>
    <description>Toxicity Endpoints</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">870</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Standard Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle
Drug: R-CHOP/R-DHAP
ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm A+I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle
Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)
ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM
2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle
Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)
2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP/R-DHAP</intervention_name>
    <description>Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)</description>
    <arm_group_label>Standard Arm A</arm_group_label>
    <arm_group_label>Experimental Arm A+I</arm_group_label>
    <arm_group_label>Experimental Arm I</arm_group_label>
    <other_name>rituximab, CHOP, DHAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib (Induction)</intervention_name>
    <description>Ibrutinib: only in cycle 1,3,5 on Day 1-19</description>
    <arm_group_label>Experimental Arm A+I</arm_group_label>
    <arm_group_label>Experimental Arm I</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASCT conditioning</intervention_name>
    <description>ASCT conditioning THAM or BEAM, stratified per site before trial activation at site
THAM (TBI (total body irradiation), Ara-C, Melphalan) or
BEAM (BCNU, Etoposide, Cytarabine, Melphalan)</description>
    <arm_group_label>Standard Arm A</arm_group_label>
    <arm_group_label>Experimental Arm A+I</arm_group_label>
    <other_name>THAM or BEAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib (Maintenance)</intervention_name>
    <description>Ibrutinib (Maintenance), daily 560 mg for 2 years;</description>
    <arm_group_label>Experimental Arm A+I</arm_group_label>
    <arm_group_label>Experimental Arm I</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients must meet the following criteria:

          -  Histologically confirmed diagnosis of MCL according to WHO classification

          -  suitable for high-dose treatment including high-dose Ara-C

          -  Stage II-IV (Ann Arbor)

          -  Age ≥ 18 years and ≤ 65 years

          -  Previously untreated MCL

          -  At least 1 measurable lesion; in case of bone marrow infiltration only, bone marrow
             aspiration and biopsy is mandatory for all staging evaluations.

          -  ECOG/WHO performance status ≤ 2

          -  The following laboratory values at screening (unless related to MCL):

               -  Absolute neutrophil count (ANC) ≥1000 cells/µL

               -  Platelets ≥100,000 cells/µL

               -  Transaminases (AST and ALT) ≤3 x upper limit of normal (ULN)

               -  Total bilirubin ≤2 x ULN unless due to known Morbus Meulengracht
                  [Gilbert-Meulengracht-Syndrome])

               -  Creatinine ≤2 mg/dL or calculated creatinine clearance ≥ 50 mL/min

          -  Written informed consent form according to ICH/EU GCP and national regulations

          -  Sexually active men and women of child-bearing potential must agree to use highly
             effective contraceptives (eg, condoms, implants, injectables, combined oral
             contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while
             on study; this should be maintained for 90 days after the last dose of study drug.

        Exclusion Criteria:

        Any potential subject who meets any of the following criteria will be excluded from
        participating in the study.

          -  Major surgery within 4 weeks prior to randomization.

          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg
             phenprocoumon).

          -  History of stroke or intracranial hemorrhage within 6 months prior to randomization.

          -  Requires treatment with strong CYP3A4/5 inhibitors.

          -  Any life-threatening illness, medical condition, or organ system dysfunction which,
             in the investigator's opinion, could compromise the subject's safety, interfere with
             the absorption or metabolism of ibrutinib capsules, or put the study outcomes at
             undue risk.

          -  Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization.

          -  Known CNS involvement of MCL

          -  Clinically significant hypersensitivity (eg, anaphylactic or anaphylactoid reactions
             to the compound of ibrutinib itself or to the excipients in its formulation)

          -  Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine
             antibodies

          -  Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or
             interferon except prephase therapy according to trial protocol

          -  Serious concomitant disease interfering with a regular therapy according to the study
             protocol:

               -  Cardiac (Clinically significant cardiovascular disease such as uncontrolled or
                  symptomatic arrhythmias, congestive heart failure, or myocardial infarction
                  within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe)
                  cardiac disease as defined by the New York Heart Association Functional
                  Classification or LVEF below LLN )

               -  Pulmonary (e.g. chronic lung disease with hypoxemia)

               -  Endocrinological (e.g. severe, not sufficiently controlled diabetes mellitus)

               -  Renal insufficiency (unless caused by the lymphoma): creatinine &gt; 2x normal
                  value and/or creatinin clearance &lt; 50 ml/min)

               -  Impairment of liver function (unless caused by the lymphoma): transaminases &gt; 3x
                  normal or bilirubin &gt; 2,0 mg/dl unless due to morbus Meulengracht
                  (Gilbert-Meulengracht-Syndrome)

          -  Patients with unresolved hepatitis B or C infection or known HIV positive infection
             (mandatory test)

          -  Prior organ, bone marrow or peripheral blood stem cell transplantation

          -  Concomitant or previous malignancies within the last 3 years other than basal cell
             skin cancer or in situ uterine cervix cancer

          -  Pregnancy or lactation

          -  Any psychological, familiar, sociological, or geographical condition potentially
             hampering compliance with the study protocol and follow up schedule

          -  Subjects not able to give consent

          -  Subjects without legal capacity who are unable to understand the nature, scope,
             significance and consequences of this clinical trial

          -  Participation in another clinical trial within 30 days before randomization in this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Dreyling, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Döndü Gözel</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>77906</phone_ext>
    <email>doendue.goezel@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Schmidt, Dr.</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>74900</phone_ext>
    <email>Christian_Schmidt@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zentralklinik Augsburg, II. Med. Klinik, Hämatologie int. Onkologie</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Schmid, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Rank, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis Dr. Janssen/Dr. Reichert in der Ubbo-Emmius-Klinik</name>
      <address>
        <city>Aurich</city>
        <zip>26603</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Janssen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dietmar Reichert, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth, Klinik f. Onkologie und Hämatologie</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Kiani, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armin Leitner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban, Klinik f. Innere Medizin, Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Scholz, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annette Dierig, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Univ.-Medizin Berlin, Med. Klinik - Hämatologie, Onkologie und Tumorimmunologie</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Pezzutto, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corinna Leng, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin-Buch, Hämatologie, Onkologie und Tumorimmunologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stephan Fuhrmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diako ev. Diakonie-KH gGmbH, Med. Klinik II, Hämatologie und Onkologie</name>
      <address>
        <city>Bremen</city>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ralf U. Trappe, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Diekmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin II</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mathias Hänel, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Thiel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DONAUISAR Klinikum Deggendorf, Innere Medizin II</name>
      <address>
        <city>Deggendorf</city>
        <zip>94469</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Graf, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Regine Maier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Mohm und Prange-Krex - Fachärzte für Innere Medizin und Hämatologie und Onkologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriele Prange-Krex, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Mohm, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik f. Hämatologie, Onkologie und klinische Immunologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guido Kobbe, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mustafa Kondakci, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Schröder, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH, Zentrum f. Innere Medizin u. internistische Onkologie, Hämostaseologie</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Herbert G. Sayer, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volker Schmidt, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elke Richter, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Med. Klinik 5, Hämatologie und internistische Onkologie</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernd Spriewald, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Krause, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik f. Hämatologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Dürig, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Carpinteiro, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Hüttmann, PD. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Klinik f. Innere Medizin, Hämatologie, Onkologie u. Stammzelltransplantation</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reinhard Marx, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna-Lena Illert, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald, Klinik u. Poliklinik f. Innere Medizin C, Hämatologie u. Onkologie-, Transplantationszentrum</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Schmidt, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Krüger, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Zentrum f. Innere Medizin, Klinik f. Hämatologie und Medizinische Onkologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wolfram Jung, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justin Hasenkamp, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katholisches Krankenhaus Hagen gGmbH, St.-Marien-Hospital, Klinik f. Hämatologie und Onkologie</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans-Walter Lindemann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cordula Maciejewski</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg, Hämatologie, Onkologie und Stammzelltransplantation</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bertram Glaß, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maike Nickelsen, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE), II. Med. Klinik u. Poliklinik, Onkologie, Hämatologie, KMT</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Judith Dierlamm, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Tomann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona, II. Med.Abt. f. Hämatologie und internistische Onkologie, Stammzelltransplantation</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans-Jürgen Salwender, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murwan Ayoub, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Med. Klinik - Innere Medizin V - Hämatologie, Onkologie und Rheumatologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mathias Witzens-Harig, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Wuchter, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Klinik f. Innere Medizin I Hämatologie &amp; Onkologie</name>
      <address>
        <city>Homburg / Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Pfreundschuh, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörg Bittenbring, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Idar-Oberstein GmbH, Medizinische Klinik I</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>55743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eva Roemer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina Bischoff, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maritza Lar-Valverde, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Jena, Klinik f. Innere Medizin II, Abteilung Hämatologie u. Internistische Onkologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul La Rose, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olaposi Youmada, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe, Med. Klinik III, Hämatologie und Onkologie</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Bentz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joy Dickinson, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik f. Innere Medizin II - Hämatologie und Onkologie</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christiane Pott, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Kneba, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftsklinikum Mittelrhein gGmbH, Ev. Stift St. Martin, Klinik f. Innere Medizin</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dirk Niemann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralph Naumann, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxisklinik f. Hämatologie und Onkologie Koblenz</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jörg Thomalla, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph von Roye, Dr,</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rudolf Weide, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kai Hübel, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Borchmann, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bastian von Tresckow, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologisch-Hämatologische Praxis Dr. Vehling-Kaiser</name>
      <address>
        <city>Landshut</city>
        <zip>84028</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ursula Vehling-Kaiser, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mike Haberkorn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut gGmbH, Med. Klinik III, Hämatologie/Internistische Onkologie</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barbara Kempf</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heiko Merkle, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caritas-KHLebach, Gemeinschaftspraxis f. Hämatologie und Onkologie, Onkologisches Zentrum Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Kremers, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Bauer, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR, selbständige Abteilung f. Hämatologie und Internistische Onkologie, Hämostaseologische Ambulanz</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dietger Niederwieser, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haifa Kathrin Al-Ali, Dr,</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Med. Klinik A</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Hoffmann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Uppenkamp, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg AöR, Klinik f. Hämatologie und Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrico Schalk, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Krogel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denise Wolleschak, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Univ. Mainz, III. Med. Klinik u. Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg Heß, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans-Joachim Beck, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes Wiesling Klinikum Minden, Klinik f. Hämatologie/Onkologie, Hämostaseologie und Palliativmedizin</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans-Heinrich Wöltjen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai Wills, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Med. Klinik und Poliklinik III</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schmidt, Dr.</last_name>
      <email>Christian_Schmidt@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Dreyling, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Schmidt, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar, III. Med. Klinik - Hämatologie und Onkologie</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Keller, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Bogner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Med. Klinik A, Translationale Onkologie / Lymphome</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg Lenz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Schliemann, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Kerkhoff, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg,5. Medizinische Klinik, Onkologie / Hämatologie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kerstin Schäfer-Eckart, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Knut Wendelin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH, Med. Klinik II</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernd Metzner, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Thole, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann Potsdam gGmbH, Zentrum f. Innere Medizin, Klinik f. Hämatologie und Onkologie</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg Maschmeyer-Krull, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Breywisch, Dr,</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KH Barmherzige Brüder, Klinik f. Onkologie und Hämatologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernhard Heilmeier, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anke Schlenska-Lange, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock, Abt. f. Hämatologie und Onkologie, Klinik und Poliklinik für Innere Medizin</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Junghanß, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Große-Thie, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Katharinenhospital, Klinik f. Hämatologie und Onkologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerald Illerhaus, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanko Cirovic</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus, Abt.f. Hämatologie und Onkologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthias Vöhringer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonja Martin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein, Hämatologie - Onkologie- Palliativmedizin</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas W. Kubin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Zettl, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen gGmbH, Okologisches Zentrum</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rolf Mahlberg, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Heidel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Med Klinik I, Innere Medizin II</name>
      <address>
        <city>Tübingen</city>
        <zip>72026</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Sökler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Müller, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Stilgenbauer, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Bloehdorn, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wolfsburg, Med. Klinik II</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steffen Neumann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nils Homann, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Med. Klinik u. Poliklinik II /ZIM</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Max S. Topp, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Düll, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mats Jerkeman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mats Jerkeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>July 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>European Mantle Cell Lymphoma Network</investigator_affiliation>
    <investigator_full_name>Prof. Dr. M. Dreyling (co-chairman)</investigator_full_name>
    <investigator_title>Sponsor Delegated Person / Coordinating Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>MCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
